8-K: Intensity Therapeutics Announces 1-for-25 Reverse Stock Split

Intensity Therapeutics, Inc. will implement a 1-for-25 reverse stock split to boost its share price and maintain Nasdaq listing compliance.

Summary

• Intensity Therapeutics, Inc. filed an amendment to its certificate of incorporation to effect a 1-for-25 reverse stock split of its common stock.
• The reverse stock split will become effective at 4:01 p.m. Eastern Time on February 18, 2026.
• Shares of common stock are expected to begin trading on a post-split basis on The Nasdaq Capital Market on February 19, 2026, under the current ticker symbol INTS.
• The primary purpose of the reverse stock split is to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
• Every twenty-five (25) shares of issued and outstanding common stock will automatically convert into one (1) share of common stock.
• No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment based on the closing sale price on The Nasdaq Capital Market on February 18, 2026.
• The number of outstanding common shares will be reduced from approximately 63,346,579 shares (as of February 12, 2026) to approximately 2,533,863 shares.
• Proportional adjustments will be made to the exercise price and number of shares issuable under outstanding stock options, warrants, convertible securities, and stock incentive plans.
• The total authorized number of shares (135,000,000 Common Stock and 15,000,000 Preferred Stock) will not change.
• The new CUSIP number for the common stock following the reverse stock split will be 45828J 202.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary but generally negative indicator. While it addresses a critical listing requirement, the need for a reverse split often reflects underlying challenges with stock performance and investor confidence.

Positives

• Action taken to regain compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.
• Maintains listing on The Nasdaq Capital Market, which is crucial for liquidity and investor confidence.

Negatives

• A reverse stock split often indicates a significantly low stock price, reflecting poor market performance or investor sentiment.
• Reduction in the number of outstanding shares can sometimes lead to decreased liquidity.
• Cash payment for fractional shares might be a minor inconvenience for some shareholders.

Risks

• Potential inability to satisfy The Nasdaq Capital Market's requirements for continued listing, leading to delisting.
• Risks related to the initiation, timing, progress, and results of future preclinical studies and clinical trials and research and development programs.
• Need to raise additional funding before generating any revenues from product sales.
• Product candidates that appear promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• Ability to maintain and establish collaborations or obtain additional funding.

Future Outlook

The company's forward-looking statements primarily relate to the risks and uncertainties associated with its clinical development programs, including the initiation, timing, progress, and results of future preclinical studies and clinical trials. It also highlights the need for future funding, the timing or likelihood of regulatory filings and approvals, and the ability of product candidates to demonstrate safety and efficacy in larger trials. The reverse stock split is a measure to ensure continued listing, which supports the company's ability to pursue these future plans.

Management Comments

• The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy for biotechnology companies, particularly those in late-stage clinical development, to maintain listing compliance on major exchanges like Nasdaq. Maintaining listing is critical for access to capital and investor visibility, especially for companies that are pre-revenue and heavily reliant on external funding for their extensive R&D pipelines, such as Intensity Therapeutics with its INT230-6 cancer therapy.

Comparison to Industry Standards

• Reverse stock splits are a standard corporate action taken by companies, including those in the biotech sector, when their stock price falls below exchange minimums (e.g., Nasdaq's $1.00 bid price requirement).
• Companies like Sorrento Therapeutics (SRNEQ) and Aeterna Zentaris (AEZS) have previously executed reverse stock splits for similar reasons.
• While it addresses a technical listing requirement, it does not fundamentally alter the company's underlying business or financial health.
• The 1-for-25 ratio is within the typical range for such actions, often chosen to achieve a sufficient post-split price buffer.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but at a proportionally higher price per share; fractional shares will be cashed out. The goal is to maintain Nasdaq listing, which benefits shareholders by preserving liquidity and market access.
• Employees (with stock options/incentives): Stock options, warrants, and convertible securities will be proportionally adjusted to reflect the split, maintaining their intrinsic value.
• Investors: The action aims to prevent delisting, which could otherwise negatively impact investor confidence and the ability to trade shares on a major exchange.

Next Steps

• Shares of common stock will begin trading on a post-split basis on The Nasdaq Capital Market on February 19, 2026.
• The Company's transfer agent, Continental Stock Transfer & Trust, will send instructions to stockholders holding physical certificates for exchanging them for new shares or cash in lieu of fractional shares.
• Continue with the Phase 3 trial in soft tissue sarcoma (the INVINCIBLE-3 Study).
• Continue with the Phase 2 study in collaboration with the Swiss Cancer Group for presurgical triple-negative breast cancer (the INVINCIBLE-4 Study).

Key Dates

Recommendation

While the reverse stock split addresses a critical Nasdaq listing requirement, preventing potential delisting, it does not fundamentally change the company's underlying business or financial prospects. The need for such an action often signals weak stock performance. Investors should hold to observe if the company can leverage its continued listing to advance its clinical programs (INT230-6) and improve its financial position, as the long-term value will depend on clinical trial success and commercialization rather than this technical adjustment.

Keywords

Reverse Stock Split, Nasdaq Compliance, Biotechnology, INTS, Stock Split, Corporate Action, SEC Filing, INT230-6, Cancer Therapy, Clinical Trials